“TXMD presented a compelling launch plan including medical, marketing and reimbursement strategies for Imvexxy to treat moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), due to menopause. The innovative launch plan leverages what we consider Imvexxy’s best-in-class profile based on safety, efficacy and convenience. According to widely accepted guidelines from regulators and clinicians, patients should begin treatment at the lowest available dose, meaning that Imvexxy should now become the first-line treatment of choice for most cases of dyspareunia. We believe TXMD has the capabilities in place to bring this vision into reality. Management provided several quantitative details which are highlighted below and detailed inside. We are impressed by the launch strategy and execution plans, and reiterate our Outperform rating with a $12 PT.”
According to TipRanks.com, Olson is a 2-star analyst with an average return of 1.2% and a 46.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
Currently, the analyst consensus on TherapeuticsMD is Strong Buy and the average price target is $15.50, representing a 164.1% upside.
In a report issued on May 23, Cantor Fitzgerald also assigned a Buy rating to the stock with a $26 price target.
The company has a one-year high of $7.01 and a one-year low of $4.04. Currently, TherapeuticsMD has an average volume of 2.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.